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Abstract: The poor prognosis of locally advanced and metastatic head and neck squamous cell carci-
noma (HNSCC) is primarily mediated by the functional properties of cancer stem cells (CSCs) and
resistance to chemoradiotherapy. We investigated whether the aldehyde dehydrogenase (ALDH)
inhibitor disulfiram (DSF) can enhance the sensitivity of therapy. Cell viability was assessed by
the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) and apoptosis assays, and the cell
cycle and reactive oxygen species (ROS) levels were evaluated by fluorescence-activated cell sorting
(FACS). The radio-sensitizing effect was measured by a colony formation assay. The synergistic
effects were calculated by combination index (CI) analyses. The DSF and DSF/Cu2+ inhibited the cell
proliferation (inhibitory concentration 50 (IC50) of DSF and DSF/Cu2+ were 13.96 µM and 0.24 µM).
DSF and cisplatin displayed a synergistic effect (CI values were <1). DSF or DSF/Cu2+ abolished
the cisplatin-induced G2/M arrest (from 52.9% to 40.7% and 41.1%), and combining irradiation (IR)
with DSF or DSF/Cu2+ reduced the colony formation and attenuated the G2/M arrest (from 53.6% to
40.2% and 41.9%). The combination of cisplatin, DSF or DSF/Cu2+, and IR enhanced the radio-chemo
sensitivity by inducing apoptosis (42.04% and 32.21%) and ROS activity (46.3% and 37.4%). DSF
and DSF/Cu2+ enhanced the sensitivity of HNSCC to cisplatin and IR. Confirming the initial data
from patient-derived tumor xenograft (PDX) supported a strong rationale to repurpose DSF as a
radio-chemosensitizer and to assess its therapeutic potential in a clinical setting.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth-most common can-
cer, accounting for over 600,000 new cases and 350,000 deaths worldwide per year [1].
Although HNSCC is highly curable at early stages, about 60% of HNSCC patients are
diagnosed with the locoregionally advanced disease (stage III or IV), which is associated
with poor survival. Local therapies, such as surgery, followed by radiation therapy (RT)
with or without concomitant chemotherapy (CT), are the key components of the initial
treatment of locally advanced (LA) HNSCC [2]. During the past decade, organ preservation
protocols with chemoradiation have also been increasingly applied, where cisplatin-based
chemotherapy is combined with concurrent locoregional radiotherapy [3]. Despite ad-
vances in the treatment of HNSCC, the survival rates have remained largely unchanged
over the past 30 years, with a five-year survival rate of less than 50%. Treatment resistance,
as well as tumor recurrence, remain critical drawbacks [4]. Therefore, there is a pressing
need to improve the treatment efficacy and develop novel treatment strategies to improve
the response to radio-chemotherapy and targeted therapies.
Disulfiram (DSF), a hydrophobic and symmetrical molecule of the dithiocarbamate
family, is available for oral administration and is approved to treat alcohol dependence [5].
DSF has a strong affinity to thiols and forms a covalent linkage with an active-site cysteine of
aldehyde dehydrogenase (ALDH), inactivating the enzyme and leading to the accumulation
of acetaldehyde, causing an aversion to alcohol [6]. Despite its multiple pharmacologic
activities, a prolonged treatment with DSF has negligible and reversible adverse effects,
and it is still considered a safe drug [7]. Particularly, DSF was recently found to have
significant anticancer activity against a number of cancer types, such as melanoma [8],
glioblastoma [9], prostate cancer [10], and breast cancer [11], both in vitro and in vivo.
An epidemiological study showed that cancer-specific mortality was 34% higher among
3038 previous DSF users (who were prescribed DSF for alcohol dependency only before
their cancer diagnosis) than among 1177 continuing users (who were prescribed DSF both
before and after diagnosis) [12].
In cells, DSF converts to diethyldithiocarbamate (deDTC), and two molecules of deDTC
bind to one molecule of Cu2+ to form the Cu [deDTC]2 complex (DSF/Cu2+) [13,14]. Cu2+
is an essential trace element for life, as it plays a crucial role in redox reactions and the
generation of reactive oxygen species (ROS) in human cells [15]. The overall stoichiometry
of the reaction with DSF:Cu2+ is a molar ratio of 1.0:0.9, which presumably could be used as
a reference when DSF acts as a copper ionophore in the substance combination. It is likely
that this may be the mechanism for the reaction of DSF with copper (II) ions under biological
conditions [16]. The copper-binding activity of DSF may also be involved in this mode
of action, because the formation of organic copper complexes appears to be responsible
for proapoptotic proteasome inhibition [14]. The observed anticancer activities of DSF
are the induction of oxidative stress, cytotoxicity due to acetaldehyde accumulation, and
proteasome and nuclear factor-κB inhibition [17]. Other proteasome inhibitors, including
deDTC, have chemo-radio-sensitizing effects, and this may also apply to DSF, further
increasing its potential as an anticancer compound [18]. Notably, DSF and its metabolites
could serve as broadly applicable and well-tolerated drugs for improving cancer treatment.
Cisplatin, one of the most widely used platinum agents, is the most common drug
for combined CT/RT treatment in HNSCC. Biologically, cisplatin binds to DNA, resulting
in adducts, and also favors the accumulation of intracellular free radicals [19]. However,
many patients show an inherent resistance to cisplatin, which may consequently lead to an
unfavorable treatment response. IR induces various DNA damage, but double-stranded
breaks have the most cytotoxic effects, which can perturb the cell cycle progression at
different stages, mainly inducing a G2/M phase arrest [20]. Moreover, even for advanced
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irradiation (IR) techniques and protocols, the control rates remain relatively low and
unpredictable [21]. In practice, one of the major challenges in RT is the prediction of the
tumor’s radio resistance in response to IR in order to optimize the given dose for the
maximal tumor cytotoxic effect and minimal damage to normal tissues [22]. Following the
treatment with cisplatin and IR, the cells were demonstrated to have a tendency to dwell
longer in the G2/M phase, and the genomic integrity of the cells is maintained by activating
the DNA repair processes before entering mitosis, which leads to increased cell survival,
so that the release from this phase could be used to push the cells into apoptosis [23,24].
Efficient DNA repair in cancer cells is an important mechanism of therapy resistance, and
therefore, the inhibition of DNA repair pathways would make cancer cells more sensitive
to DNA-damaging agents like CT and RT [25].
To determine the potential of DSF in cancer therapy, it is important to dissect its various
mechanisms of action and unravel the possible synergistic effects in combination with other
therapeutic modalities. Here, we investigated a treatment strategy for DSF or DSF/Cu2+
in combination with cisplatin and IR against HNSCC cell lines in order to confirm their
potent radio-chemo-sensitizing activity in vivo and chemo-sensitizing capability in vivo
with a murine model employing xenotransplanted primary human HNSCC.
2. Materials and Methods
2.1. Cell Lines and Cell Culture
UM-SCC9, UM-SCC47, UMSCC11B (University of Michigan, Ann Arbor, MI, USA),
and UT-SCC33 (University of Turku, Turku, Finland) were cultured in RPMI 1640 medium
(Gibco, New York, NY, USA) supplemented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (Biochrom GmbH, Berlin, Germany). Cells were incubated at 37 ◦C in a
humidified incubator with 95% air and 5% CO2 until 70–80% confluence. Cells were washed
with phosphate-buffered saline (PBS) twice and detached with 0.5%/0.02% trypsin/EDTA
(Ethylenediaminetetraacetate) solution (Biochrom, GmbH, Berlin, Germany). The reaction
was stopped by adding the complete culture medium. After centrifugation at 200× g for
5 min, cells were prepared for the experiments or resuspended in a new culture medium
for passage for future cultivation.
2.2. Reagents
DSF and copper (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in dimethyl
sulfoxide (DMSO; Sigma-Aldrich, Steinheim, Germany) and distilled water at a 10-mM
stock concentration. Both of them were stored at −20 ◦C and freshly diluted to a working
solution in the culture medium before use. We added DMSO solvent at an equivalent
concentration in each control experimental group. The highest final concentration of DMSO
in the viability experiments was 0.3%, which was low enough to not induce any effects,
especially not apoptosis. The ratio of DSF and Cu2+ was set at 1:1 in all experiments.
2.3. 1-(4,5-Dimethylthiazol-2-yl)-3,5-Diphenylformazan (MTT) Cytotoxicity Assay
Cells were seeded in 96-well plates at a density of 4000 cells/well in triplicates. The
MTT assay was performed at the end of the 24–72-h incubation period. In brief, 10 µL
of MTT labeling reagent were added to each well. After 4 h of incubation, 100 µL of
solubilization solution was added to each well, and incubation was continued overnight.
Optical density was measured using a Bio-Rad (Hercules, CA, USA) microplate reader at a
595-nm wavelength. The cell viability (%) data was averaged and normalized against the
untreated control samples.
2.4. Apoptosis Assessment
The apoptotic status was determined by an Annexin-V-FLUOS Staining Kit (Roche,
Mannheim, Germany) using fluorescence-activated cell sorting (FACS; BD FACS Caliber
Berlin, Germany) following the manufacturer’s protocol and analyzed by FlowJo V10
software (Becton Dickinson, Heidelberg, Germany). Cells were incubated in a 24-well
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plate at a density of 3 × 104/mL for the indicated time intervals. Subsequently, cells were
harvested and suspended at a density of 1 × 107 cells/mL in 100-µL binding buffer
containing 20-µL Annexin-V and 20-µL propidium iodide (PI) at room temperature in the
dark for 15 min. Apoptosis and necrosis were evaluated using fluorescence channel 3 (FL3)
(PI) and Fluorescence channel 1 (FL1) (Annexin-V). The percentage of cells was assessed
in 4 quadrants: lower left (Annexin-V−/PI−) was presented for live cells, lower right
(Annexin-V+/PI−) for early apoptosis, upper right (Annexin-V+/PI+) for late apoptosis,
and upper left (Annexin-V−/PI+) for necrotic cells, respectively.
2.5. Cell Cycle Analysis
Cells were exposed to various combinations of treatment for 48 h and subsequently
harvested by trypsinization. After stopping the reaction with PBS plus 3% FBS, cells were
fixed in 70% cold ethanol at 4 ◦C overnight. After two steps of PBS washing, samples were
incubated with PI (1 mg/mL, Sigma, Darmstadt, Germany), RNase (10 mg/mL, Sigma,
Darmstadt, Germany), and 1% Triton (Sigma-Aldrich, USA) for 30 min in the dark at room
temperature. PI fluorescence of each sample was measured by flow cytometry with a
488-nm excitation wavelength, and the DNA content was analyzed using FlowJo software.
2.6. Measurement of Reactive Oxygen Species (ROS) Activity
Following 24 h of incubation with different drug combinations, cells were harvested
and stained with MitoSOX Red Mitochondrial Superoxide Indicator (Molecular Probes/Invitrigen,
Eugene, OR, USA) at 37 ◦C in a humidified incubator for 15 min. After incubation, samples
were washed three times with PBS and analyzed by flow cytometry. Gated markers of ROS
activity were set for the percentage of ROS activity in control cells incubated with MitoSOX
reagent but without any drug treatment.
2.7. Irradiation (IR)
Cells were seeded in various treatment combinations 4 to 5 h before exposure to
IR for dosages of 2, 4, 6, or 10 Gy using a medical linear accelerator (Clinac 600 C/D,
Varian, Palo Alto, CA, USA) with a 6-MV (MeV, Million electron Volts) photon beam at
2.76 Gy/min. All samples were maintained in tissue culture flasks and positioned in a
water tank for backscatter saturation of the beam to the flasks. An 8-cm-thick solid block of
a water-equivalent material was put on the top of the plates to ensure that the photon dose
was applied homogenously to the cells. Colony formation and ROS activity testing were
performed 24 h after IR; cell cycle progression and apoptosis assessment were measured
48 h after IR.
2.8. Clonogenicity Survival Assay
Cells were incubated for an additional 24 h after IR. The added drug was completely
removed by washing, and cells were reseeded in 6-well plates with fresh culture medium.
After 9–12 days, the medium was removed, and colonies were washed with PBS twice
before fixation by methanol and staining with 0.5% crystal violet. The number of colonies
consisting of at least 50 cells was recorded.
The survival fraction (SF) was calculated as follows: mean number of colonies
counted/(number of cells inoculated *plating efficiency). Plating efficiency (PE) is de-
fined as the mean number of colonies observed/number of cells inoculated for untreated
controls. The cell survival curves were obtained by fitting into the linear-quadratic model
(LQ model) using GraphPad Prism software (GraphPad Software Inc., San Diego, CA,
USA) in formula Y = exp(−(a*x + b*(x2))).
2.9. Spheroid Formation Assay
Cells were seeded in a cell culture flask onto a coated surface with 10% agarose in
serum-free medium 263 (PAA, Laboratories GmbH, Heidelberg, Germany) supplemented
with 10-ng/mL epidermal growth factor (EGF) and 10-ng/mL basic fibroblast growth
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factor (bFGF) (Biochrom, GmbH, Berlin, Germany). For passaging to at least the second
generation or for the following experiments, spheroids were collected with a 40-µM mesh
filter (Costar/Corning, Lowell, MA, USA) and were then dissociated into single cells by
5-min incubation with trypsin/EDTA at 37 ◦C in a water bath. The reaction was stopped by
adding complete medium. Single cells were washed and plated into fresh culture medium
under the same conditions.
For the spheroid formation assay, cells were treated with DSF or DSF/Cu2+ in 24-well
ultra-low attachment plates (Corning, Costar, NY, USA) at the density of 2 × 104 cells/mL
for 3 days and photographed at 50-fold magnification. Spheroids of 200 µm or more in
diameter were counted.
2.10. In Vivo Evaluation
The patient-derived tumor xenograft (PDX) models were established at EPO Berlin-
Buch GmbH (Berlin, Germany) and propagated subcutaneously in NMRI (nu/nu) mice.
EPO is fully accredited by the AAALAC (Association of Assessment and Accreditation of
Laboratory Animal Care). For transplantation, the tumor was harvested and cut into small
fragments. This study was approved by the local Institutional Review Board of Charité
University Medicine, Berlin, Germany (EA4/019/12). All animal experiments were carried
out in accordance with the United Kingdom coordinating committee on cancer research
regulations for the welfare of animals and the German Animal Protection Law and were
also approved by the local responsible authorities (LaGeSoBerlin, A0452/08).
The in vivo efficacy of disulfiram as a monotherapy and in combination with cisplatin
was assessed in 3 PDX models of HNSCC using a setting with one mouse per model per
arm. Tumor fragments of similar sizes (2 × 2 mm) were transplanted subcutaneously to
NMRI nu/nu mice. At a palpable tumor size of 200 mm3, the mice (n = 1 to 2 per group) were
treated with disulfiram (60 mg/kg/s.c.(subcutaneous injection)) three times a week and/or
cisplatin (8 mg/kg, i.v. (intravenous injection)) once a week (Q7D). Mice in the vehicle
group received 0.9% NaCl. Tumor growth was monitored two times a week by measuring
the tumor volume [(width2 × length)/2] using a caliper. Treatment was continued over a
period of 3 weeks, unless tumor size exceeded 2000 mm3 or animals showed a loss of body
weight over 10%. Tumor volumes at the end of treatment compared to the beginning were
used as the sensitivity parameter. Relative tumor volume (RTV) resembles tumor growth
over the course of treatment (relative tumor volume in comparison to the timepoint of
treatment initiation).
2.11. Statistical Analysis and Calculation of Drug Interactions
Statistical software GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA,
USA) was used for all statistical analyses. Values represent the mean ± standard deviation
(SD) of at least duplicated wells in at least three independent experiments. Figures show
results of one out of three representative experiments. Comparisons among multiple
groups were performed using the one-way ANOVA test. A probability level of * p < 0.05
was recognized as statistically significant.
The combination index (CI) method according to Chou-Talalay was applied to evaluate
the drug interactions, which are based on the multiple drug effect equation derived from the
median-effect principle of the mass-action law [26]. It provided quantitative determination
for synergism (CI < 1), the additive effect (CI = 1), and antagonism (CI > 1) and established
the algorithm using CompuSyn software (CompuSyn Inc., New York, NY, USA) for the
automated simulation of drug combinations.
3. Results
3.1. DSF Inhibits Cells Proliferation in a Dose- and Time-Dependent Manner
UM-SCC9, UM-SCC47, UM-SCC11B, and UT-SCC33 were treated with DSF in a range
of concentrations (0.001–100 µM) for 72 h. As shown in Figure 1A, the viability of the
cells was significantly reduced after exposure to DSF in a dose-dependent manner. The
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cytotoxicity increased linearly with the increasing DSF concentrations in all four tested cell
lines. The IC50 (Inhibitory concentration 50) values were 13.96 µM, 13.43 µM, 11.24 µM, and
15.06 µM for the cell lines UM-SCC9, UM-SCC47, UM-SCC11B, and UT-SCC33, respectively.
The cytotoxic effect exerted by DSF was also dependent on the time of exposure. When
exposed to different concentrations of DSF (0.1–30 µM) for 24 h, 48 h, and 72 h, the average
IC50 values of DSF in UM-SCC9 were 24.94, 18.74, and 15.32 µM; 21.91, 16.62, and 15.69 µM
in UM-SCC47; 32.10, 20.05, and 14.43 µM in UM-SCC11B; and 41.95, 23.89, and 15.19 µM
in UT-SCC33, respectively (Figure 1B). The IC50 value at 24 h in each of the cell lines was
significantly higher than that at 48 h or 72 h. Altogether; these results confirm that the
cytotoxic effects of DSF in HNSCC cell lines shows a dose- and time-dependent effect.
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 Figure 1. Cytotoxicity and reactive oxygen species (ROS) generation of disulfiram (DSF) or DSF/Cu2+. (A) Cells were
exposed to different concentrations of DSF for 72 h and subjected to the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan
(MTT) assay, n = 3. (B) Cells were exposed to different concentrations of DSF (0.1–30 µM) at the indicated time intervals.
The levels of IC50 were measured by the MTT assay. * p < 0.05 and ** p < 0.01, n = 3, one-way ANOVA, compared to 24 h.
(C) Cells were exposed to different treatments for 72 h, and the viability was measured by the MTT assay, n = 3. (D) Cells
were exposed to DSF/Cu2+ (1 µM) at the indicated time intervals. The apoptotic cell population was identified by the
Annexin/V-PI (propidium iodide) assay. ** p < 0.01, n = 2, one-way ANOVA, compared to 4 h. (E) Cells were exposed to
different concentrations of DSF or DSF/Cu2+ for 24 h; then, the ROS activity was measured. * p < 0.05 and ** p < 0.01, n = 2,
one-way ANOVA, compared to the control.
3.2. Copper (II) Significantly Increases DSF-Mediated Cytotoxicity in a Dose- and
Time-Dependent Manner
Even though DSF alone had no significant cytotoxic effect at concentrations lower
than 1 µM (Figure 1A), its cytotoxicity was markedly enhanced when the medium was
supplemented with copper (II). As shown in Figure 1C, compared to Cu2+ or DSF alone,
combined DSF/Cu2+ exposure was highly cytotoxic, with an IC50 of 0.24 µM, 0.193 µM,
0.267 µM, and 0.27 µM in UM-SCC9, UM-SCC47, UM-SCC11B, and in UT-SCC33, respec-
tively. The IC50 value of the DSF/Cu2+ treatment over 72 h is approximately 50-fold lower
than that of DSF alone.
Next, the apoptosis induced by DSF/Cu2+ treatment was evaluated. An Annexin-V/PI
dual-staining apoptosis assay was performed following an up to 72-h incubation. As shown
in Figure 1D and Supplementary Figure S1, both the proportion of early (Annexin-V+/PI−,
lower/right quadrant) and in late apoptosis (Annexin-V+/PI+, upper/right quadrant)
increased during the course of the treatments. A substantial increase of cytotoxicity was
detected following a 24-h or longer incubation. We thus conclude that DSF and Cu2+ in com-
bination are remarkably more cytotoxic than their individual components. Nevertheless,
the effect is time-dependent.
3.3. ROS Activity Mediates DSF or DSF/Cu2+-Induced Cytotoxicity
To assess whether DSF or DSF/Cu2+-induced apoptosis is mediated by intracellular
ROS formation, the ROS activity was measured with increasing concentrations of DSF
(1–100 µM) or DSF/Cu2+ (0.1–1 µM). As shown in Figure 1E and Supplementary Figure S3,
The ROS activity intensified with the increasing concentrations of DSF or DSF/Cu2+. More
ROS was generated when the DSF concentration was elevated from 10 µM (33.1%, 35.1%,
36.9%, and 32.6%) to 100 µM (98.1%, 97.6%, 97.9%, and 98.5% in UM-SCC9, UM-SCC47,
UM-SCC11B, and UT-SCC33, respectively). Importantly, the combination of DSF (1 µM)
and Cu2+ (1 µM) resulted in a strikingly enhanced ROS accumulation; the effect was similar
to that observed in cells treated with 100 µM of DSF alone. These findings suggest that
DSF or DSF/Cu2+-induced cytotoxicity is mediated by the generation of intracellular ROS.
Moreover, the addition of Cu2+ enhances ROS production about 100-fold compared to
DSF alone.
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3.4. DSF or DSF/Cu2+ Does Not Interfere with Cell Cycle Progression
To analyze the mechanisms underlying the cytotoxic effects of DSF or DSF/Cu2+, the
cell cycle progression was investigated. Since the cell cycle phases were compromised
and disappeared at high drug concentrations, the concentrations used for this assay were
selected for each cell line based on the IC50 values to avoid excessive apoptosis during
exposure. As shown in Supplementary Figure S2, cells were treated with different concen-
trations of DSF (0.1–3 µM) or DSF/Cu2+ (0.01–0.1 µM). The proportions of cells in the G1, S,
and G2/M phases did not significantly change compared to the untreated controls. These
results indicate that either DSF alone or in combination with Cu2+ does not affect the cell
cycle progression of HNSCC cell lines under the experimental conditions used.
3.5. DSF Enhances Cisplatin Cytotoxicity
We further investigated whether DSF and cisplatin have an impact compound in the
treatment. The cytotoxicity of DSF (5 µM) and cisplatin in combination was significantly
higher than that of cisplatin alone (Figure 2A). To understand the essence of this combina-
torial effect, the Chou-Talalay method was used to distinguish different interactions, as
described in Methods. As shown in Table 1, the combination of DSF and cisplatin yielded a
synergistic effect (CI < 1) in all four tested cell lines in a broad concentration at ED50 and
ED75 (effective dose). These observations provide strong evidence that DSF synergistically
reduces cell proliferation and enhances the cytotoxicity of cisplatin.
Table 1. Disulfiram (DSF) and cisplatin shows synergistic cytotoxicity.
Cisplatin + DSF
Combination Index (CI) a at
ED50 ED75




a CI for DSF plus cisplatin compared to individual application. CI = 1 indicates an additive effect, CI < 1 indicates
a synergistic effect, and CI > 1 indicates an antagonistic effect.
3.6. DSF or DSF/Cu2+ Inhibits Cisplatin-Induced G2/M Phase Arrest
To gain a better understanding of the cytotoxic effects induced by DSF or DSF/Cu2+,
the cell cycle progression was assessed following a 48-h treatment with cisplatin in the
presence of DSF or DSF/Cu2+. As seen in Figure 2B,C, cisplatin enhanced the G2/M
blockade, which resulted in an increased number of cells in the G2/M phase and in a
reduced number of cells in G1/G0 as well. A highly pronounced G2/M phase arrest was
seen in the three tested cell lines (30.0–52.9% in UM-SCC9, 31.3–56.4% in UM-SCC47,
and 23.6–56.9% in UT-SCC33). However, when the cells were treated with cisplatin in
combination with 5 µM of DSF or 0.1 µM of DSF/Cu2+, the number of cells in the G2/M
populations decreased, with a parallel increase in the number of cells in the G1 phase. A
significant abrogation was observed from 52.9% to 40.7% and 41.1% in UM-SCC9, from
56.4% to 43.1% and 42.5% in UM-SCC47, and from 56.9% to 42.3% and 45.6% in UT-SCC33.
Collectively, DSF or DSF/Cu2+ partly reverse this cisplatin-induced blocking and resulted
in a lower proportion of cells in the G2/M phase.
3.7. Radio-Sensitizing Effects of DSF or DSF/Cu2+
To determine whether DSF or DSF/Cu2+ increase the sensitivity of HNSCC cells to IR,
cells were pretreated with increasing concentrations of DSF or DSF/Cu2+, then exposed
to IR (10 Gy) and rested for 72 h. Dose response curves showed an increased cytotoxicity
when DSF or DSF/Cu2+ were combined with IR (Figure 3A).




Figure 2. Combination treatment with DSF or DSF/Cu2+ and cisplatin. (A) Cells were exposed to different concentrations
of cisplatin with DSF (5 µM) for 72 h, and the cytotoxicity was measured by the MTT assay, n = 3. (B) Cells were exposed to
DSF (5 µM), DSF/Cu2+ (0.1 µM), cisplatin (UM-SCC9 and UM-SCC47: 0.3 µM and UT-SCC33: 0.6 µM), or a combination of
both for 48 h. (C) The percentage distribution of cells in the G2/M phase is compared. ## p < 0.01: cisplatin vs. control and
* p < 0.05: cisplatin vs. cisplatin + DSF or cisplatin + DSF/Cu2+, n = 2, one-way ANOVA.
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Figure 3. Radio-sensitizing effect of DSF or DSF/Cu2+. (A) Cells were pretreated with different concentrations of DSF or 
DSF/Cu2+ and then irradiated with 10 Gy. Viability was measured by the MTT assay after 72 h, n = 3. (B) Cells were pre-
treated with DSF (1 μM) or DSF/Cu2+ (0.1 μM) and then irradiated with 2–6 Gy. After 24 h, cells were reseeded in the drug-
free medium for 9–12 days. The surviving fraction was compared using the formula of the linear-quadratic (LQ) model. 
(C) Cells were exposed to different dosages of IR, and then, the cell cycle distribution was measured 48 h later. (D) Cells 
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To evaluate the stemness, epithelial cells from stablished cells lines were investigated 
for their ability to grow independently in an anchorage. This spheroid formation assay 
was performed to measure the activity of stem cells and to investigate the potential effect 
Figure 3. Radio-sensitizing effect of DSF or DSF/Cu2+. (A) Cells were pretreated with different concentrations of DSF or DSF/Cu2+
and then irradiated with 10 Gy. Viability was measured by the MTT assay after 72 h, n = 3. (B) Cells were pretreated with DSF (1 µM)
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surviving fraction was compared using the formula of the linear-quadratic (LQ) model. (C) Cells were exposed to different dosages of
IR, and then, the cell cycle distribution was measured 48 h later. (D) Cells were pretreated with DSF (5 µM) or DSF/Cu2+ (0.1 µM)
before being exposed to IR (10 Gy). After recovering for a further 48 h, the levels of each cell cycle phase were determined. (E) The
percentage of cells in the G2/M phase was compared. ## p < 0.01: IR vs. control and * p < 0.05: IR vs. IR + DSF or IR + DSF/Cu2+, n = 2,
one-way ANOVA.
To investigate whether DSF or DSF/Cu2+ could exhibit a radio-sensitizing effect, we
incubated cells with DSF (1 µM) or DSF/Cu2+ (0.1 µM) before exposing them to a graded
dosage of IR. Cell survival following IR was shown in Figure 3B. DSF and DSF/Cu2+
strongly inhibited HNSCC clonogenicity to uch an extent that few clones could be solated
and counted to establish the curve with this combination therapy. Taken together, these
findings demonstrate both DSF and DSF/Cu2+ significantly increased the cy otoxic eff ts
of IR in the HNSCC cell lines.
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3.8. Treatment with DSF or DSF/Cu2+ Reduces IR-Induced G2/M Phase Arrest
To explore the potential mechanism underlying the radio-sensitizing effect of DSF or
DSF/Cu2+, we analyzed their impact on IR-induced changes in the cell cycle progression.
First, we measured the cell cycle status when cells were exposed to increasing dosages of
IR (Figure 3C). After a relatively high dose, such as 20 Gy, most cells were blocked in the
G2/M phase (63.1% in UM-SCC9, 62.4% in UM-SCC47, and 48.8% in UM-SCC11B).
To determine whether DSF or DSF/Cu2+ reactivates the cell cycle progression through
G2/M and therefore potentially sensitizes cells to IR, DSF (5 µM) or DSF/Cu2+ (0.1 µM)
was added to the culture of UN-SCC9 and UM-SCC47 cell lines prior to IR (Figure 3D,E).
At 48 h post-IR, an activation of G2/M arrest occurred from 27.7% to 53.6% in UM-SCC9
and from 28.2% to 50.0% in UM-SCC47, with a concomitant drop in the number of cells
in the G1 phase. In contrast, in cells pretreated with 5-µM DSF or 0.1-µM DSF/Cu2+, IR
resulted in a decreased fraction in the G2/M populations from 53.6% to 40.2% and 41.9%
in UMS-CC9 and from 50.0% to 39.5% and 39.7% in UM-SCC47. In conclusion, these
observations suggest that a pretreatment with DSF or DSF/Cu2+ attenuate the IR-induced
G2/M phase arrest.
3.9. Cytotoxicity of the Combined Treatment with DSF or DSF/Cu2+, Cisplatin, and IR
The above presented experiments demonstrate that DSF or DSF/Cu2+ enhanced the
cytotoxicity of cisplatin and IR by reversing the G2/M checkpoint arrest and reducing the
colony formation. These results prompted us to investigate the effects of triple treatment by
using a combination capacity of DSF or DSF/Cu2+, cisplatin, and IR. As shown in Figure 4A
and Supplementary Figure S4, DSF (5 µM) or DSF/Cu2+ (0.1 µM) in combination with
cisplatin (2.5 µM) induced the apoptotic cells 34.71% and 26.69% in UM-SCC9, 31% and
25.48% in UM-SCC47, and 37.55%, and 31.77% in UM-SCC11B. Thus, a treatment with DSF
or DSF/Cu2+ pushed cisplatin-damaged cells into apoptosis. More importantly, we proved
in the previously shown experiments (Figure 2A) that the viability of the cells at 2.5-µM
cisplatin was nearly 80%, and here, we also indicated that apoptosis at 2.5-µM cisplatin was
lower than 20%. In contrast, when combined with DSF, even at this low concentration of
cisplatin, a statistically significant stronger toxicity was induced. In addition, a substantial
increase of apoptosis was found when combined with IR. Apoptosis of 42.04% and 32.21%
was observed in IR + cisplatin + DSF and IR + cisplatin + DSF/Cu2+ in UM-SCC9, 43.9%
and 31.91% in UM-SCC47, and 45.37% and 38.08% in UM-SCC11B. This impact of DSF or
DSF/Cu2+ on the cytotoxicity as seen in the triple-combination treatments emphasizes the
potential clinical use of this strategy to counteract chemo-radio-resistance, leading to better
therapeutic outcomes.
3.10. Combination of DSF, DSF/Cu2+, Cisplatin, and IR Enhances ROS Generation
Based on the cytotoxic effect of the triple treatment shown above, we hypothesized
that the ROS level may correspond to the apoptotic rate induced by DSF or DSF/Cu2+.
Compared with each treatment alone, the combined DSF (5 µM) with cisplatin (2.5 µM)
increased the ROS levels to 38.7% in UM-SCC9, 35.8% in UM-SCC47, and 35.9% in UM-
SCC11B, respectively (Figure 4B and Supplementary Figure S5). IR is also an essential
element for ROS generation. When combined with IR, cisplatin and DSF or DSF/Cu2+
further increased the ROS activity to 46.3% and 37.4% in UM-SCC9, 44.0% and 32.5% in
UM-SCC47, and 46.3% and 34.7% in UM-SCC11B, respectively. Taken together, these results
indicate that a triple treatment of DSF or DSF/Cu2+ with cisplatin and IR significantly
increases the cytotoxicity in the HNSCC cell lines by enhancing the ROS accumulation.
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3.11. DSF or DSF/Cu2+ Inhibits Spheroid Formation
To evaluate the stemness, epithelial cells from stablished cells lines were investigated
for their ability to grow independently in an anchorage. This spheroid formation assay
was performed to measure the activity of stem cells and to investigate the potential effect
of the DSF or DSF/Cu2+ treatment on the self-renewal capacity of the HNSCC cell lines.
As shown in Figure 4A,B, an abundance of large spheroids grew from untreated controls
in all three tested cell lines. We observed small inattentive spheroids and loose cellular
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aggregates when cells were exposed to DSF (10 µM) or DSF/Cu2+ (0.15 µM) for three
days, and the ability of the spheroid formation was remarkably reduced, which indicated
a reduced proliferative potential of the cancer stem cells (CSCs) (Figure 5). The number
of spheroids was significantly reduced from an average of 39 to 19 and 21 in UM-SCC9,
from an average of 42 to 21 and 24 in UM-SCC47, and from an average of 36 to 20 and 18 in
UM-SCC11B, respectively. In conclusion, a DSF or DSF/Cu2+ treatment could inhibit the
formation and growth of spheroids, indicating their possible inhibition of self-renewal in
HNSCC CSCs.
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Figure 5. DSF or DSF/Cu2+ inhibits spheroid formation in the head and neck squamous cell carcinoma (HNSCC) cell
lines. (A) Cells were exposed to DSF or DSF/Cu2+ for 72 h, and representative image are shown (×50 magnifi ation).
(B) Histogram shows the statistical analysis of spheroid numbers. ** p < 0.01 one-way ANOVA compared to control.
3.12. DSF Induced Growth Inhibition of HNSCC-Derived PDX Models
For further evaluation of the DSF effects in vivo, we propagated three different HN-
SCC PDX models and treated the mice with disulfiram and cisplatin separately and in
combination in a pilot trial to support the feasibility murine model using HNSCC xeno-
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transplants. These results confirm an effective oral application route resulting in sufficient
(tumor) tissue levels for a treatment evaluation with cisplatin-based chemotherapy and
radiation. As shown in Figure 6, compared to the controls, mice were treated with DSF
alone or in combination with cisplatin to reach the therapeutic levels in mice and at the
tumor site. Future testing of our in vitro data for statistical significance of additives or
synergistic effects using combination therapies is warranted.




Figure 6. DSF induced the growth inhibition in HNSCC-derived patient-derived tumor xenograft (PDX) models. Three 
independently derived permanently growing PDX models from a primary HNSCC tumor were transplanted onto severe 
combined immune deficiency (SCID) mice and single animals, each treated by DSF, cisplatin, or a combination. Tumor 
volumes were measured twice a week. 
Figure 6. DSF induced the growth inhibition in HNSCC-derived patient-derived tumor xenograft (PDX) models. Three
independently derived permanently growing PDX models from a primary HNSCC tumor were transplanted onto severe
combined immune deficiency (SCID) mice and single animals, each treated by DSF, cisplatin, or a combination. Tumor
volumes were measured twice a w ek.
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4. Discussion
The current treatment strategies for HNSCC are surgery combined with radiation or
chemotherapy. However, approximately 50% of patients who are initially treated will de-
velop therapy-resistant recurrent tumors within two years after treatment, providing a poor
prognosis [27,28]. The development of effective strategies to counteract resistance, reduce
toxicity, and to improve clinical outcome are urgently needed. Our study demonstrates the
high potential of DSF or DSF/Cu2+ as a chemo-radio-sensitizing agent for HNSCC in vitro.
We identified that the viability of HNSCC cells was inhibited by DSF, and the addition
of Cu2+ further enhanced this cytotoxicity in a dose- and time-dependent manner. These
observations were consistent with previous findings that DSF has anticancer activity and
that copper potentiates its activity in vitro and in vivo [9,14].
In particular, our findings showed that DSF synergistically reduced the cellular pro-
liferation and enhanced the cisplatin-induced cytotoxicity. Cisplatin is a platinum-based
compound that forms both intra- and inter-strand DNA adducts that have a broad spectrum
of antitumor activity and are widely used in the treatment of various malignant tumors [29].
Although it has long been used throughout history, a successful cisplatin treatment has
two major obstacles—severe toxicity and acquired resistance [30]. It is well-known that a
cellular sensitivity to chemotherapeutic agents relies on DNA damage and deregulated
cell cycle kinetics allowing damaged cells to undergo mitosis, leading to cell death [31].
Cisplatin is a potent cytotoxic agent that induces cell death by directly damaging DNA,
which covalently binds DNA to form bulky adducts that block replication and transcrip-
tion, resulting in G2 phase cell cycle arrest [32]. Attenuation of the G2 checkpoint and
subsequently enhanced cytotoxicity nicely fits with the rationale that unrepaired DNA
damage will eventually lead to a loss of clonogenicity and result in cell death [20]. We
found that the cell cycle was blocked at G2/M when the cells were exposed to cisplatin,
and an additional treatment by DSF or DSF/Cu2+ could partially reverse this blocking.
Our results thus indicate that DSF or DSF/Cu2+ may prevent G2/M cell cycle checkpoint
activation and, thus, sensitize the tumor cells to cisplatin treatment.
We observed that, after treatment with IR, the G2/M cell fractions were increased in a
dosage-dependent manner, which suggests a greater checkpoint activation in response to
DNA damage. We further demonstrated that DSF or DSF/Cu2+ potentiated the efficacy of
IR through attenuating the G2/M arrest to inhibit IR-induced G2 checkpoint activation,
which could enable more damaged cells to enter mitosis without appropriate repair for
a further accumulation of DNA damage and thereby significantly enhance the cytotoxic
efficacy of IR. This hypothesis may constitute a potential mechanism underlying the
cisplatin- or IR-enhancing effects of DSF or DSF/Cu2+ in HNSCC cell lines.
IR induces DNA double-strand breaks and typically activates the G2/M checkpoint,
which arrests cells in the G2/M phase. This arrest provides time to repair DNA dam-
age and to prevent mitotic catastrophes and apoptosis [33]. Abrogation of the G2/M
checkpoint has been regarded as a clinically exploitable strategy to achieve tumor-specific
radio-sensitization [34]. In particular, critical thiols in effectors of DNA repair, the cell cycle
checkpoint, and other pathways linked to the cellular response to IR are possible targets for
DSF or DSF/Cu2+-induced radio-sensitization [35]. Many studies have shown that abroga-
tion of the G2 checkpoint can potentiate cell death induced by IR [36] or DNA-damaging
agents [37], which supports the G2 checkpoint as a potential therapeutic target that may sen-
sitize cells to chemo- and radiotherapy. Moreover, a DSF or DSF/Cu2+ treatment strongly
decreased the clonogenicity and, in conjunction with IR, resulted in significantly fewer
clones isolated and counted. Those findings indicate that DSF or DSF/Cu2+ could be used
to synergize with IR in a combination therapy.
Our data demonstrated that DSF or DSF/Cu2+ alone or in combination with cisplatin
and IR significantly increased the intracellular ROS accumulation, which further supported
DSF as a novel combination treatment regimen for HNSCC treatment. ROS contains a
group of oxygen-containing chemical species normally generated from the mitochondrial
respiratory chain reaction with reactive chemical properties [38]. ROS affects cellular pro-
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cesses such as proliferation, senescence, and apoptosis that contribute to the development
of cancer [39]. Owing to the high proliferative rate and energy requirements, cancer cells
are under higher ROS stress than their normal counterparts. High levels of ROS can dam-
age DNA, the mitochondrial inner membrane, and membrane phospholipids, leading
to apoptosis [40]. It has been demonstrated that a further exposure of ROS induced by
ROS-generating agents (such as DSF or DSF/Cu2+) could exhaust the cellular antioxidant
capacity, pushing tumor cells over the tolerated ROS threshold and selectively leading to
apoptosis in tumor cells [41]. Interestingly, the stemness of the established HNSCC cell
lines was significantly reduced after treatment with DSF or DSF/Cu2+. We suppose that
cancer stem cells that are characterized by high levels of ALDH expression are especially
vulnerable to DSF treatment and ROS generation. This, in turn, could lead to reduced
tumor growth capacity and less therapy resistance.
Our study further implicated DSF as a potential drug targeting HNSCC. In recently
established PDX models from HNSCC primary tumors, the DSF treatment showed a
remarkable growth retardation that was significant in two out of three independent models.
This effect was retained in all combination therapy models with cisplatin demonstrating
both the sufficient tumor tissue levels of DSF and cisplatin alone in vivo and in combination
for tumor treatment evaluation, bearing in mind that the observed induction of apoptosis
by DSF in vitro is important for the design of murine in vivo trials. However, due to
the cisplatin sensitivity and the limited number of mice used, no synergistic effect could
be demonstrated at this point. These data, although generated in an initial pilot trial,
already show promise for an applicability of DSF for HNSCC therapy. A study evaluating
combination treatment regimens statistically will be needed for characterization of the
therapeutic potential in preparation of clinical trials.
Indeed, the anticancer activity of DSF appears promising in clinical trials in various
malignancies. An initial assessment of DSF in combination with cisplatin in non-small cell
lung cancer was recently completed (NCT 00312819). The results indicated that patients
receiving additional DSF treatment showed increased survival. A phase II trial is investigat-
ing the effect of DSF in a newly diagnosed glioblastoma multiform (NCT 01777919). Other
phase I clinical trials of DSF in refractory solid tumors, including liver (NCT 00742911),
melanoma metastases (NCT 00256230), and prostate cancer (NCT 01118741), are still under-
going. The development of a novel anticancer drug against various malignant tumors is
both a time-consuming and costly procedure. Finding a novel therapeutic use for an “old”
drug has attracted attention, owing to being fast tracked, and may lead to the discovery
of new biological processes or disease pathways [42]. DSF has been an FDA-approved
drug to treat alcoholism for over 60 years, since 1951. It could be a promising strategy for
repositioning it as a prospective drug or adjuvant treatment for sensitization in combination
with other chemo or radio treatments to overcome resistances to single compounds. Even
though the impressive physiological tolerance of DSF and its powerful anticancer effects
has caught the attention of researchers for years, the development of DSF-based clinical
applications against tumor diseases still needs to move forward, including for HNSCC.
The obstacles in this path are the instability of DSF in the gastric environment and its
rapid degradation by glutathione reductase, which appears to cause unfavorable pharma-
cokinetics and pharmacodynamics, hampering its further development as an anticancer
drug [43]. Clinical studies have demonstrated that, after a single oral dose of 500 mg or
repeated doses of 250 mg, the plasma concentrations of DSF were less than 2 µM [17].
Therefore, an efficient drug delivery system is essential for the clinical application of DSF
in cancer treatment. One strategy would be the encapsulation of DSF into nanoparticles to
protect it from degradation in the blood system. The targeted delivery of DSF-encapsulated
nanoparticles into tumor cells could increase the drug accumulation at the tumor site
and would enhance the endurance of the drug in the blood circulation [9,44]. Due to the
intrinsic Cu2+ distribution inside the cells and the ROS modulative property, a low dosage
of DSF could already oxidize the cancer cells to death, especially when oxidative stress is
imposed. This implies that a higher concentration may not be necessary for cancer ther-
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apy. Instead, proper doses of DSF matched with Cu2+ are more important. Therefore, the
ROS-independent mechanism is expected to be rather important at clinically achievable
concentrations, and the carefully controlled titration of DSF and its derivatives for cancer
treatment remain to be investigated.
In summary, we demonstrated that DSF or DSF/Cu2+ could induce cytotoxicity in
a dose- and time-dependent manner and that the cytotoxic effect was mediated by ROS
generation. Further, we showed that DSF or DSF/Cu2+ sensitized HNSCC cells towards IR
and the cisplatin treatment effectively and partially reversed the protective G2/M phase
cell cycle arrest. Due to its intrinsic cytotoxic and radio-chemo-sensitizing effects, DSF or
DSF/Cu2+ could be used as a radio-chemo sensitizer to overcome the therapeutic resistance
and, thus, improve the successful treatment of HNSCC in the future.
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